260 related articles for article (PubMed ID: 17118807)
1. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors.
Gertsch J; Raduner S; Altmann KH
J Recept Signal Transduct Res; 2006; 26(5-6):709-30. PubMed ID: 17118807
[TBL] [Abstract][Full Text] [Related]
2. CB receptor ligands from plants.
Woelkart K; Salo-Ahen OM; Bauer R
Curr Top Med Chem; 2008; 8(3):173-86. PubMed ID: 18289087
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological actions of cannabinoids.
Pertwee RG
Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 cannabinoid receptor affinity and receptor activation.
Berglund BA; Fleming PR; Rice KC; Shim JY; Welsh WJ; Howlett AC
Drug Des Discov; 2000; 16(4):281-94. PubMed ID: 10807034
[TBL] [Abstract][Full Text] [Related]
5. Cannabichromene is a cannabinoid CB
Udoh M; Santiago M; Devenish S; McGregor IS; Connor M
Br J Pharmacol; 2019 Dec; 176(23):4537-4547. PubMed ID: 31368508
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
7. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands.
Raitio KH; Salo OM; Nevalainen T; Poso A; Järvinen T
Curr Med Chem; 2005; 12(10):1217-37. PubMed ID: 15892633
[TBL] [Abstract][Full Text] [Related]
8. Behavioral effects of cannabinoid agents in animals.
Chaperon F; Thiébot MH
Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
[TBL] [Abstract][Full Text] [Related]
9. Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.
Durdagi S; Reis H; Papadopoulos MG; Mavromoustakos T
Bioorg Med Chem; 2008 Aug; 16(15):7377-87. PubMed ID: 18595717
[TBL] [Abstract][Full Text] [Related]
10. Virtual Screening of
Mizera M; Latek D; Cielecka-Piontek J
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722631
[TBL] [Abstract][Full Text] [Related]
11. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.
Poso A; Huffman JW
Br J Pharmacol; 2008 Jan; 153(2):335-46. PubMed ID: 17982473
[TBL] [Abstract][Full Text] [Related]
12. Oxa-adamantyl cannabinoids.
Ho TC; Tius MA; Nikas SP; Tran NK; Tong F; Zhou H; Zvonok N; Makriyannis A
Bioorg Med Chem Lett; 2021 Apr; 38():127882. PubMed ID: 33636308
[TBL] [Abstract][Full Text] [Related]
13. Indoles and related compounds as cannabinoid ligands.
Manera C; Tuccinardi T; Martinelli A
Mini Rev Med Chem; 2008 Apr; 8(4):370-87. PubMed ID: 18473928
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids and the skeleton: from marijuana to reversal of bone loss.
Bab I; Zimmer A; Melamed E
Ann Med; 2009; 41(8):560-7. PubMed ID: 19634029
[TBL] [Abstract][Full Text] [Related]
15. CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches.
Ortega-Gutiérrez S; López-Rodríguez ML
Mini Rev Med Chem; 2005 Jul; 5(7):651-8. PubMed ID: 16026311
[TBL] [Abstract][Full Text] [Related]
16. CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.
Smoum R; Baraghithy S; Chourasia M; Breuer A; Mussai N; Attar-Namdar M; Kogan NM; Raphael B; Bolognini D; Cascio MG; Marini P; Pertwee RG; Shurki A; Mechoulam R; Bab I
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8774-9. PubMed ID: 26124120
[TBL] [Abstract][Full Text] [Related]
17. Selective cannabinoid receptor 2 modulators: a patent review 2009--present.
Riether D
Expert Opin Ther Pat; 2012 May; 22(5):495-510. PubMed ID: 22537079
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.
Bhattacharjee H; Gurley SN; Moore BM
Bioorg Med Chem Lett; 2009 Mar; 19(6):1691-3. PubMed ID: 19230659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
